Optinose has announced the appointments of Ricci Whitlow as Vice President of Technical Operations, Harry Sacks as VP of Medical Affairs and Corporate Medical Officer, John Peterkins as VP of Market Access, David Fabbri as VP of Sales, and Andrew Muzsi as VP of Marketing.
Optinose CEO Peter Miller said, “Our success depends on our people and our culture. Adding these leaders to our organization will strengthen our ability to execute as we prepare for the planned second quarter 2018 launch of Xhance.”
Whitlow was most recently VP of Operations for Softgel/DDS at Catalent Pharma Solutions. Sacks was most recently VP of Clinical Development at Edge Therapeutics and was previously VP and Head of Respiratory, US Medical Affairs at Novartis. Peterkins and Fabbri both come most recently from Sun Pharma where Peterkins was VP, Market Access, and Fabbri was VP of Sales, Dermatology. Muzsi was most recently Payer, Strategy, and Operations lead for Eliquis at Bristol Meyers Squibb.
All except for Sacks worked for Johnson & Johnson for a number of years at some point in their careers.
Read the Optinose press release.
